Literature DB >> 7945962

Reversal of sexual exhaustion by serotonergic and noradrenergic agents.

G Rodríguez-Manzo1, A Fernández-Guasti.   

Abstract

The possible participation of the serotonergic and the noradrenergic systems in the control of the inhibitory state present during sexual satiation was studied from a pharmacological perspective. It was found that the 5-HT1A agonist 8-OH-DPAT and the alpha 2 adrenoceptor antagonist, yohimbine were effective in reversing the sexual inhibition resulting from sexual exhaustion. These findings show that the inhibition present during satiation is reversible and suggest that central mechanisms underlie it. The serotonergic as well as the noradrenergic systems, probably through their 5-HT1A and alpha 2 receptors, respectively, play a role in the establishment of this phenomenon. Additionally, the main features of the development of sexual exhaustion were reviewed. It was found that sexual exhaustion has two different expressions: a major proportion of the exhausted rats does not copulate and a third part of this population is able to execute one ejaculatory series from which they do not recover. The data are discussed in terms of the motivational and consummatory components of male sexual behaviour.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945962     DOI: 10.1016/0166-4328(94)90019-1

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  11 in total

1.  Nucleus accumbens dopamine increases sexual motivation in sexually satiated male rats.

Authors:  Irma Lorena Guadarrama-Bazante; Gabriela Rodríguez-Manzo
Journal:  Psychopharmacology (Berl)       Date:  2018-12-08       Impact factor: 4.530

Review 2.  The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

Authors:  Sheryl A Kingsberg; Anita H Clayton; James G Pfaus
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

3.  Low anandamide doses facilitate male rat sexual behaviour through the activation of CB1 receptors.

Authors:  Ana Canseco-Alba; Gabriela Rodríguez-Manzo
Journal:  Psychopharmacology (Berl)       Date:  2014-03-27       Impact factor: 4.530

4.  Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats.

Authors:  D F Fiorino; A Coury; A G Phillips
Journal:  J Neurosci       Date:  1997-06-15       Impact factor: 6.167

5.  The nucleus accumbens dopamine increase, typically triggered by sexual stimuli in male rats, is no longer produced when animals are sexually inhibited due to sexual satiety.

Authors:  Ana Canseco-Alba; Ulises Coffeen; Orlando Jaimes; Francisco Pellicer; Gabriela Rodríguez-Manzo
Journal:  Psychopharmacology (Berl)       Date:  2022-10-03       Impact factor: 4.415

6.  Opioid antagonists and the sexual satiation phenomenon.

Authors:  G Rodríguez-Manzo; A Fernández-Guasti
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

7.  Fos expression in monoaminergic cell groups in response to sociosexual interactions in male and female Japanese quail.

Authors:  Onur Iyilikci; Samantha Baxter; Jacques Balthazart; Gregory F Ball
Journal:  Behav Neurosci       Date:  2014-02       Impact factor: 1.912

Review 8.  Molecular signaling involved in regulating feeding and other motivated behaviors.

Authors:  Todd R Gruninger; Brigitte LeBoeuf; Yishi Liu; L Rene Garcia
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

9.  Do rats have orgasms?

Authors:  James G Pfaus; Tina Scardochio; Mayte Parada; Christine Gerson; Gonzalo R Quintana; Genaro A Coria-Avila
Journal:  Socioaffect Neurosci Psychol       Date:  2016-10-25

10.  Prosexual Effect of Chrysactinia mexicana A. Gray (Asteraceae), False Damiana, in a Model of Male Sexual Behavior.

Authors:  R Estrada-Reyes; O A Ferreyra-Cruz; G Jiménez-Rubio; O T Hernández-Hernández; L Martínez-Mota
Journal:  Biomed Res Int       Date:  2016-08-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.